title: Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan.
abstract: BACKGROUND
  The efficacy of hepatic arterial infusion chemotherapy for the treatment of advanced hepatocellular carcinoma (HCC) remains unclear.
  
  
  METHODS
  The outcome of 476 patients with HCC who underwent hepatic arterial infusion chemotherapy with 5-fluorouracil and cisplatin (HAIC) were compared with 1466 patients who did not receive active therapy.
  
  
  RESULTS
  A survival benefit of the therapy after adjusting for known risk factors was observed (hazard ratio, 0.48; 95% CI, 0.41-0.56; P<0.0001). In propensity score-matched analysis (n=682), median survival time was longer for patients who underwent chemotherapy (14.0 months) than for patients who did not receive active treatment (5.2 months, P<0.0001).
  
  
  CONCLUSIONS
  For advanced HCC, HAIC is considered to be an effective treatment.
authors.affiliation: Department of Molecular Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Nouso
authors.forename: K
authors.initials: K
authors.lastname: Miyahara
authors.forename: D
authors.initials: D
authors.lastname: Uchida
authors.forename: K
authors.initials: K
authors.lastname: Kuwaki
authors.forename: N
authors.initials: N
authors.lastname: Izumi
authors.forename: M
authors.initials: M
authors.lastname: Omata
authors.forename: T
authors.initials: T
authors.lastname: Ichida
authors.forename: M
authors.initials: M
authors.lastname: Kudo
authors.forename: Y
authors.initials: Y
authors.lastname: Ku
authors.forename: N
authors.initials: N
authors.lastname: Kokudo
authors.forename: M
authors.initials: M
authors.lastname: Sakamoto
authors.forename: O
authors.initials: O
authors.lastname: Nakashima
authors.forename: T
authors.initials: T
authors.lastname: Takayama
authors.forename: O
authors.initials: O
authors.lastname: Matsui
authors.forename: Y
authors.initials: Y
authors.lastname: Matsuyama
authors.forename: K
authors.initials: K
authors.lastname: Yamamoto
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000627:therapeutic use; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D007564:Japan; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D002945:Cisplatin; D005472:Fluorouracil